January 14, 2025

Global Gastric Cancer Burden Shifts Younger

Significant gender disparities in the GC incidence exist with higher incidence and mortality rates noted in men compared to women across different age groups.

Conexiant

January 07, 2025

Do Probiotics Impact Cancer Survival?

Moderate intake of dietary probiotics was inversely associated with cancer mortality,’ highlighting dose-specific effects seen in a 20-year NHANES analysis.

Conexiant

January 07, 2025

Genitourinary Cancer Expert Yüksel Ürün, MD, Shares His Career Journey and the Importance of Achieving a Work/Life Balance

In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with medical oncologist Yüksel Ürün, MD, about his clinical and research career in oncology...

The ASCO Post

January 06, 2025

Medical Editors Sound Alarm on Fake Journals

"Particularly vulnerable authors are those who are early in their careers, lack experience and adequate mentorship, and face pressure to publish" — top medical journal editors expose how predatory publishers exploit researchers.

Conexiant

January 03, 2025

Surgeon General Issues Advisory on Alcohol, Cancer Link

Of all breast cancer cases in the U.S., 16.4% are directly linked to alcohol consumption.

Conexiant

December 20, 2024

Is Surgery Necessary for Low-Risk DCIS?

“If these results hold up over time, most patients who have this type of low-risk disease will have the option of avoiding invasive treatments."

Reuters

December 18, 2024

Doctor Unions Surge Tenfold Since 2023

The number of physicians seeking to unionize has spiked in recent years.

Conexiant

December 18, 2024

Understanding the 2022 WHO Classification of Endocrine Tumors

From the parathyroid to adrenal glands and thyroid tumors, the latest WHO classification introduces essential updates to tumor nomenclature and diagnostic criteria.

Conexiant

November 08, 2023

Cabozantinib for Pretreated Patients With Advanced Neuroendocrine Tumors: CABINET Trial

Detailed results from CABINET (Alliance A021602), a phase III pivotal trial evaluating cabozantinib compared with placebo in two cohorts of previously treated patients with neuroendocrine tumors, were...

The ASCO Post